Skip to content
Search

Latest Stories

Lords back amendment to exempt pharmacies from national insurance hike

Members of the House of Lords approved four changes to the National Insurance Contributions (Secondary Class 1 Contributions) Bill at the report stage

National Insurance Bill debated in the the House of Lords

National Insurance Bill debated in the the House of Lords

Pharmacies are expected to be exempted from national insurance contributions following an amendment to the National Insurance Contributions (Secondary Class 1 Contributions) Bill, which was approved by the House of Lords on Tuesday, 25 February 2025.

In the 2024 Autumn Budget, Chancellor Rachel Reeves announced an increase in the employer secondary Class 1 National Insurance contributions rate, rising from 13.8% to 15% starting in April 2025.


Health and care providers, including community pharmacists, have been calling on the government to reconsider their decision and grant them an exemption from the increase.

Malcolm Harrison, chief executive of the Company Chemists’ Association (CCA) welcomed the strong backing for this amendment in the Lords, stating: “It is absolutely right that pharmacies should be exempted from the increase to National Insurance contributions.”

He pointed out that pharmacy businesses earn as much as 90-95% of their income by delivering NHS care and services, but the amount that the government pays for these services has not increased since 2014.

“As increased operating costs cannot be passed on to the NHS or to patients, pharmacy businesses have been forced to simply absorb them.

“We urge Peers to pass this amendment and hope that MPs will also follow suit.”

Nick Kaye, Chair of the National Pharmacy Association (NPA), emphasised that this amendment would help pharmacies manage a looming bill of hundreds of millions of pounds.

"This comes in the context of 40 per cent cuts to pharmacy budgets, forcing record numbers to close,” he said.

Kaye reiterated that if the government fails to provide additional support in the new contract, they would be forced to recommend pharmacies to cut back services, including their opening hours, to protect their businesses.

The NPA estimated that rises in National Insurance and the National Living Wage would collectively cost pharmacies across the UK £310 million.

Baroness Barker, who introduced the amendment, warned that sudden changes to national insurance, along with the increases in the minimum wage, could threaten “the existence of large numbers of providers and have a profound impact on budgets.”

Lords voted to agree four changes to the Bill aimed at maintaining current national insurance contribution rates or granting exemptions from the planned increase. These changes apply to:

  • Health and care providers, including GPs, dentists and pharmacists
  • Charities with annual revenue less than £1 million
  • Transport providers for children with special educational needs and disabilities
  • Low earning or low employee businesses and organisations.

Additionally, members agreed to increase employment allowance in the early years sector to £20,000 and require

However, two proposed amendments—one on new contribution rates for part-time workers and another on maintaining current rates for sectors such as universities, councils, and housing associations—were put to a vote but rejected.

The Third Reading, which ensures the new law is effective, workable and without loopholes, is scheduled for 4 March.

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less